{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:23:51Z","timestamp":1772119431105,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00520-024-08750-6","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:01:37Z","timestamp":1721779297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of universal hepatitis B virus (HBV) screening using chemotherapy orders on the HBV reactivation in cancer patients"],"prefix":"10.1007","volume":"32","author":[{"given":"C\u00e9line","family":"Marty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Martel-Laferri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Doucet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"8750_CR1","doi-asserted-by":"publisher","first-page":"m2200","DOI":"10.1136\/bmj.m2200","volume":"370","author":"Y Shi","year":"2020","unstructured":"Shi Y, Zheng M (2020) Hepatitis B virus persistence and reactivation. BMJ 370:m2200. https:\/\/doi.org\/10.1136\/bmj.m2200","journal-title":"BMJ"},{"issue":"221\u2013244","key":"8750_CR2","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT (2015) American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148(221\u2013244):e223. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.038","journal-title":"Gastroenterology"},{"key":"8750_CR3","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba R, Liang TJ (2017) Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 152:1297\u20131309. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.009","journal-title":"Gastroenterology"},{"key":"8750_CR4","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1200\/JCO.20.01757","volume":"38","author":"JP Hwang","year":"2020","unstructured":"Hwang JP, Feld JJ, Hammond SP et al (2020) Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol 38:3698\u20133715. https:\/\/doi.org\/10.1200\/JCO.20.01757","journal-title":"J Clin Oncol"},{"key":"8750_CR5","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/JCO.2015.61.3745","volume":"33","author":"JP Hwang","year":"2015","unstructured":"Hwang JP, Somerfield MR, Alston-Johnson DE et al (2015) Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol 33:2212\u20132220. https:\/\/doi.org\/10.1200\/JCO.2015.61.3745","journal-title":"J Clin Oncol"},{"key":"8750_CR6","unstructured":"Administration FaD (2013) FDA drug safety communication: boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). http:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-boxed-warning-and-new-recommendations-decrease-risk-hepatitis-b."},{"key":"8750_CR7","doi-asserted-by":"publisher","first-page":"15629","DOI":"10.1038\/s41598-018-34111-5","volume":"8","author":"J Lee","year":"2018","unstructured":"Lee J, Park JY, Kim DG et al (2018) Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. Sci Rep 8:15629. https:\/\/doi.org\/10.1038\/s41598-018-34111-5","journal-title":"Sci Rep"},{"key":"8750_CR8","doi-asserted-by":"publisher","first-page":"e0120749","DOI":"10.1371\/journal.pone.0120749","volume":"10","author":"A Visram","year":"2015","unstructured":"Visram A, Chan KK, McGee P et al (2015) Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. PLoS One 10:e0120749. https:\/\/doi.org\/10.1371\/journal.pone.0120749","journal-title":"PLoS One"},{"key":"8750_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","volume":"5","author":"SD Ramsey","year":"2019","unstructured":"Ramsey SD, Unger JM, Baker LH et al (2019) Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol 5:497\u2013505. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6437","journal-title":"JAMA Oncol"},{"key":"8750_CR10","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1200\/JOP.2011.000450","volume":"8","author":"JP Hwang","year":"2012","unstructured":"Hwang JP, Fisch MJ, Zhang H et al (2012) Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract 8:e32-39. https:\/\/doi.org\/10.1200\/JOP.2011.000450","journal-title":"J Oncol Pract"},{"key":"8750_CR11","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/1471-2407-13-534","volume":"13","author":"JP Hwang","year":"2013","unstructured":"Hwang JP, Fisch MJ, Lok AS et al (2013) Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 13:534. https:\/\/doi.org\/10.1186\/1471-2407-13-534","journal-title":"BMC Cancer"},{"key":"8750_CR12","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/annonc\/mdw414","volume":"27","author":"CS Voican","year":"2016","unstructured":"Voican CS, Mir O, Loulergue P et al (2016) Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 27:2172\u20132184. https:\/\/doi.org\/10.1093\/annonc\/mdw414","journal-title":"Ann Oncol"},{"key":"8750_CR13","unstructured":"Rossy Cancer Network: hepatitis B screening before treatment with rituximab (2018) https:\/\/www.mcgill.ca\/rcr-rcn\/scorecard\/quality-dimension\/safety\/s1-hepatitis-b-screening-treatment-rituximab."},{"key":"8750_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP et al (2015) American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:215\u2013219. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.039","journal-title":"Gastroenterology"},{"key":"8750_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/M15-1121","volume":"164","author":"S Paul","year":"2016","unstructured":"Paul S, Saxena A, Terrin N et al (2016) Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med 164:30\u201340. https:\/\/doi.org\/10.7326\/M15-1121","journal-title":"Ann Intern Med"},{"key":"8750_CR16","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","volume":"125","author":"GK Lau","year":"2003","unstructured":"Lau GK, Yiu HH, Fong DY et al (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742\u20131749. https:\/\/doi.org\/10.1053\/j.gastro.2003.09.026","journal-title":"Gastroenterology"},{"key":"8750_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.21024","volume":"43","author":"JW Jang","year":"2006","unstructured":"Jang JW, Choi JY, Bae SH et al (2006) A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 43:233\u2013240. https:\/\/doi.org\/10.1002\/hep.21024","journal-title":"Hepatology"},{"key":"8750_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/hep.22106","volume":"47","author":"C Hsu","year":"2008","unstructured":"Hsu C, Hsiung CA, Su IJ et al (2008) A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin\u2019s lymphoma: a randomized trial. Hepatology 47:844\u2013853. https:\/\/doi.org\/10.1002\/hep.22106","journal-title":"Hepatology"},{"key":"8750_CR19","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","volume":"31","author":"YH Huang","year":"2013","unstructured":"Huang YH, Hsiao LT, Hong YC et al (2013) Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31:2765\u20132772. https:\/\/doi.org\/10.1200\/JCO.2012.48.5938","journal-title":"J Clin Oncol"},{"key":"8750_CR20","doi-asserted-by":"publisher","first-page":"30642","DOI":"10.18632\/oncotarget.8907","volume":"7","author":"MY Zhang","year":"2016","unstructured":"Zhang MY, Zhu GQ, Shi KQ et al (2016) Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget 7:30642\u201330658. https:\/\/doi.org\/10.18632\/oncotarget.8907","journal-title":"Oncotarget"},{"key":"8750_CR21","first-page":"501","volume":"15","author":"C Yang","year":"2016","unstructured":"Yang C, Qin B, Yuan Z et al (2016) Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol 15:501\u2013511","journal-title":"Ann Hepatol"},{"key":"8750_CR22","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s11096-016-0358-6","volume":"38","author":"S Yu","year":"2016","unstructured":"Yu S, Luo H, Pan M et al (2016) Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm 38:1035\u20131043. https:\/\/doi.org\/10.1007\/s11096-016-0358-6","journal-title":"Int J Clin Pharm"},{"key":"8750_CR23","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ et al (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67:1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800","journal-title":"Hepatology"},{"key":"8750_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver. Electronic address eee and European Association for the Study of the L uropean","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee and European Association for the Study of the L uropean (2017) EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67:370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"key":"8750_CR25","first-page":"1","volume":"57","author":"CM Weinbaum","year":"2008","unstructured":"Weinbaum CM, Williams I, Mast EE et al (2008) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57:1","journal-title":"MMWR Recomm Rep"},{"issue":"e13495","key":"8750_CR26","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1111\/ecc.13495","volume":"30","author":"K Leber","year":"2021","unstructured":"Leber K, Otten H, Brandjes DPM et al (2021) Clinical practice of hepatitis B screening in patients starting with chemotherapy: a survey among Dutch oncologists. Eur J Cancer Care (Engl) 30(e13495):2021. https:\/\/doi.org\/10.1111\/ecc.13495","journal-title":"Eur J Cancer Care (Engl)"},{"key":"8750_CR27","first-page":"19","volume":"77","author":"K Leber","year":"2019","unstructured":"Leber K, Otten J, Depla A et al (2019) Introduction of routine hepatitis B screening for all patients receiving cancer treatment. Neth J Med 77:19\u201324","journal-title":"Neth J Med"},{"key":"8750_CR28","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2011.40.7510","volume":"30","author":"U Zurawska","year":"2012","unstructured":"Zurawska U, Hicks LK, Woo G et al (2012) Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 30:3167\u20133173. https:\/\/doi.org\/10.1200\/JCO.2011.40.7510","journal-title":"J Clin Oncol"},{"key":"8750_CR29","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1200\/JCO.2011.35.1635","volume":"29","author":"FL Day","year":"2011","unstructured":"Day FL, Karnon J, Rischin D (2011) Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 29:3270\u20133277. https:\/\/doi.org\/10.1200\/JCO.2011.35.1635","journal-title":"J Clin Oncol"},{"key":"8750_CR30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/jco.2013.31.31_suppl.158","volume":"31","author":"LK Hicks","year":"2013","unstructured":"Hicks LK, Leung P, Cape J (2013) Screening for hepatitis B virus prior to chemotherapy: a quality improvement project. J Clin Oncol 31:158\u2013158. https:\/\/doi.org\/10.1200\/jco.2013.31.31_suppl.158","journal-title":"J Clin Oncol"},{"key":"8750_CR31","doi-asserted-by":"crossref","first-page":"609A","DOI":"10.1016\/j.jhep.2012.09.021","volume":"58","author":"MK Sammons","year":"2013","unstructured":"Sammons MK, Patel D, Sepkowitz K et al (2013) Successful implementation of a universal screening program to prevent hepatitis B reactivation in a large cancer center: 848. Hepatology 58:609A-610A","journal-title":"Hepatology"},{"key":"8750_CR32","unstructured":"Centers for Disease Control: Yellow Book, (2020) https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2024\/infections-diseases\/hepatitis-b."},{"key":"8750_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/cld.426","volume":"5","author":"A Visram","year":"2015","unstructured":"Visram A, Feld JJ (2015) Defining and grading HBV reactivation. Clin Liver Dis (Hoboken) 5:35\u201338. https:\/\/doi.org\/10.1002\/cld.426","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"8750_CR34","unstructured":"Public Health Agency of Canada (2019) Report on Hepatitis B and C in Canada: 2016. Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada, https:\/\/www.canada.ca\/content\/dam\/themes\/health\/publications\/diseases-conditions\/report-hepatitis-b-c-canada-2016\/report-hepatitis-b-c-canada-2016.pdf."},{"issue":"29","key":"8750_CR35","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1186\/s40780-015-0030-7","volume":"1","author":"A Sanagawa","year":"2015","unstructured":"Sanagawa A, Kuroda J, Shiota A et al (2015) Outcomes of the implementation of the computer-assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis. J Pharm Health Care Sci 1(29):2016. https:\/\/doi.org\/10.1186\/s40780-015-0030-7","journal-title":"J Pharm Health Care Sci"},{"key":"8750_CR36","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/1055-9965.EPI-18-0448","volume":"27","author":"E Chak","year":"2018","unstructured":"Chak E, Taefi A, Li CS et al (2018) Electronic medical alerts increase screening for chronic hepatitis B: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 27:1352\u20131357. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0448","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"8750_CR37","first-page":"279","volume":"82","author":"AS Koksal","year":"2019","unstructured":"Koksal AS, Toka B, Eminler AT et al (2019) The efficacy of a computer alert programme for increasing HBV screening rates before starting immunosuppressive therapy. Acta Gastroenterol Belg 82:279\u2013284","journal-title":"Acta Gastroenterol Belg"},{"key":"8750_CR38","doi-asserted-by":"publisher","first-page":"552","DOI":"10.5152\/tjg.2023.22297","volume":"34","author":"AS Koksal","year":"2023","unstructured":"Koksal AS, Toka B, Sadecolak M et al (2023) Electronic alert system significantly increases HBV screening rates before immunosuppressive treatments. Turk J Gastroenterol 34:552\u2013559. https:\/\/doi.org\/10.5152\/tjg.2023.22297","journal-title":"Turk J Gastroenterol"},{"key":"8750_CR39","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1038\/s41598-020-59476-4","volume":"10","author":"M Riveiro-Barciela","year":"2020","unstructured":"Riveiro-Barciela M, Gubern P, Roade L et al (2020) An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders. Sci Rep 10:3038. https:\/\/doi.org\/10.1038\/s41598-020-59476-4","journal-title":"Sci Rep"},{"key":"8750_CR40","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/hep4.1238","volume":"2","author":"A Jasmine Bullard","year":"2018","unstructured":"Jasmine Bullard A, Cunningham FE, Volpp BD et al (2018) Preventing hepatitis B reactivation during anti-CD20 antibody treatment in the veterans health administration. Hepatol Commun 2:1136\u20131146. https:\/\/doi.org\/10.1002\/hep4.1238","journal-title":"Hepatol Commun"},{"key":"8750_CR41","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3390\/jcm11092446","volume":"11","author":"A Asai","year":"2022","unstructured":"Asai A, Hirai S, Yokohama K et al (2022) Effect of an electronic alert system on hepatitis B virus reactivation in patients receiving immunosuppressive drug therapy. J Clin Med 11:2022. https:\/\/doi.org\/10.3390\/jcm11092446","journal-title":"J Clin Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08750-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08750-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08750-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T01:09:14Z","timestamp":1723597754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08750-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["8750"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08750-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3909095\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"29 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research involving human participants and\/or animals approval by the CHUM research and ethics committee was obtained prior to data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"C\u00e9line Marty and Jean-Philippe Adam had no disclosure. Val\u00e9rie Martel-Laferri\u00e8re is supported by the program Clinical Research Scholars\u2014Junior 2 of FRQS, has received consultant honoraria from Abbvie and research grants from Gilead and Merck  St\u00e9phane Doucet has received speaker or consultant honoraria from Abbvie Canada, Astra Zeneca, Gilead, Merck, Roche, BMS, Lundbeck, Janssen, Seattle Genetics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"541"}}